1229 related articles for article (PubMed ID: 16424172)
1. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
2. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
3. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
4. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
5. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
Kleindienst P; Brocker T
J Immunol; 2003 Mar; 170(6):2817-23. PubMed ID: 12626531
[TBL] [Abstract][Full Text] [Related]
6. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.
Schnell S; Young JW; Houghton AN; Sadelain M
J Immunol; 2000 Feb; 164(3):1243-50. PubMed ID: 10640737
[TBL] [Abstract][Full Text] [Related]
7. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
Herrera OB; Brett S; Lechler RI
Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
[TBL] [Abstract][Full Text] [Related]
8. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
9. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
10. Major histocompatibility complex (MHC) class II-peptide complexes arrive at the plasma membrane in cholesterol-rich microclusters.
Bosch B; Heipertz EL; Drake JR; Roche PA
J Biol Chem; 2013 May; 288(19):13236-42. PubMed ID: 23532855
[TBL] [Abstract][Full Text] [Related]
11. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
Zhou G; Ding ZC; Fu J; Levitsky HI
J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
[TBL] [Abstract][Full Text] [Related]
12. Activation of Dendritic Cells Alters the Mechanism of MHC Class II Antigen Presentation to CD4 T Cells.
Cho KJ; Ishido S; Eisenlohr LC; Roche PA
J Immunol; 2020 Mar; 204(6):1621-1629. PubMed ID: 31996461
[TBL] [Abstract][Full Text] [Related]
13. Immune complex-mediated antigen presentation induces tumor immunity.
Rafiq K; Bergtold A; Clynes R
J Clin Invest; 2002 Jul; 110(1):71-9. PubMed ID: 12093890
[TBL] [Abstract][Full Text] [Related]
14. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.
Dolan BP; Phelan TP; Ilkovitch D; Qi L; Wade WF; Laufer TM; Ostrand-Rosenberg S
J Immunol; 2004 Jan; 172(2):907-14. PubMed ID: 14707062
[TBL] [Abstract][Full Text] [Related]
15. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
16. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
[TBL] [Abstract][Full Text] [Related]
17. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Dissanayake SK; Tuera N; Ostrand-Rosenberg S
J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
19. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.
Derouazi M; Di Berardino-Besson W; Belnoue E; Hoepner S; Walther R; Benkhoucha M; Teta P; Dufour Y; Yacoub Maroun C; Salazar AM; Martinvalet D; Dietrich PY; Walker PR
Cancer Res; 2015 Aug; 75(15):3020-31. PubMed ID: 26116496
[TBL] [Abstract][Full Text] [Related]
20. Forced expression of HLA-DM at the surface of dendritic cells increases loading of synthetic peptides on MHC class II molecules and modulates T cell responses.
Pezeshki AM; Côté MH; Azar GA; Routy JP; Boulassel MR; Thibodeau J
J Immunol; 2011 Jul; 187(1):74-81. PubMed ID: 21622867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
